Research use only · EU-warehoused · COA on every batch · HPLC ≥99% · Shipment 2–5 days
Log in Register
Home/ Catalogue/ Combination Blends/ BPC-157 + TB-500
In stock
BPC-157 + TB-500

BPC-157 + TB-500

Lyophilised · ≥99% (HPLC) ·

Quantity Volume discounts auto-applied
Custom quantity
1
Shipping to EuropeDispatched from our EU facility in Slovakia, so EU destinations clear no third-country customs. Packeta, DPD or DHL Express depending on country — handling 1–2 business days; typical transit is 1 day in Slovakia, about 2 days to CZ/AT/HU/PL/DE, 1–3 days elsewhere in the EU/EEA, and 2–4 days to non-EU Europe plus local customs. Shipping is calculated at checkout and VAT is shown before you pay.

Supplied lyophilised. Reconstitution typically uses bacteriostatic water.

How to reconstitute BPC-157 + TB-500 — stock calculator
Independently third-party tested · COA on every batch · 48h EU dispatch
[01]

Overview

Format: co-formulated lyophilised vial, 10 mg + 10 mg. One sealed vial of freeze-dried BPC-157 and TB-500 (the fragment Ac-LKKTETQ, thymosin β4 residues 17–23) in a single cake, prepared in the laboratory as one solution. The BPC-157 here is not the arginate salt. Looking for fixed, pre-weighed units of the pair, with BPC-157 as the arginate salt? That is a separate product: BPC-157 Arginate + TB-500 Capsules.

BPC-157 + TB-500 is a dual-peptide research blend combining BPC-157 (Body Protection Compound-157), a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV; CAS 137525-51-0; MW 1419.5 g/mol) derived from human gastric juice, with TB-500, the synthetic N-acetylated heptapeptide Ac-LKKTETQ corresponding to residues 17–23 — the actin-binding motif — of thymosin β4 (CAS 885340-08-9; MW 889.0 g/mol). Both components are supplied lyophilised at ≥99% purity by HPLC. For laboratory research use only; not for human or veterinary use.

This blend pairs two of the most extensively investigated peptides in regenerative and cytoprotective research, BPC-157 and TB-500, in a single co-formulated vial. The combination is studied because the two molecules act through largely distinct mechanisms — one rooted in gastric cytoprotection, the other in actin-binding cell motility — making them a frequent pairing in tissue-repair model systems.

Two repair peptides with separate origins. BPC-157 is a synthetic pentadecapeptide derived from a protective protein in gastric juice, characterised as a pleiotropic, stable agent in a large experimental literature (Sikiric et al., 2024). TB-500 here is the synthetic acetylated 17–23 fragment of thymosin β4 (Ac-LKKTETQ) — the same molecule as Condor’s TB-500 (Frag), not the full-length protein — taken from a naturally occurring actin-sequestering peptide expressed across many human tissues during development (Faa et al., 2024).

What the research explores. Each component has its own body of experimental work, and together they are studied across complementary repair themes:

  • Tendon, ligament & bone repair (BPC-157) — investigated for effects on tendon outgrowth and cell migration, ligament healing, and bone-defect models (Chang et al., 2011; Cerovecki et al., 2010; Sebecić et al., 1999).
  • Gastrointestinal cytoprotection (BPC-157) — studied for attenuation of experimentally induced gastric lesions (Petek et al., 1999).
  • Cell migration & organ-repair signalling (thymosin β4 and its 17–23 motif) — the parent protein has been examined in wound-healing, renal, and broader regenerative contexts (He et al., 2026; Mason et al., 2023; Xing et al., 2021); the 17–23 motif carried by TB-500 has been linked to endothelial migration in vitro (Philp et al., 2003), and evidence for the isolated fragment remains limited.

All of the activity described here comes from in-vitro and animal studies; these findings characterise biological behaviour in experimental models and do not demonstrate efficacy or safety in humans. Full citations are listed under the Scientific References tab.

Specification & quality. Each individually sealed vial contains 10 mg of BPC-157 and 10 mg of TB-500 as a white lyophilized powder at ≥99% purity by HPLC, soluble in water. Every batch is third-party tested, and a Certificate of Analysis (COA) is available. Store at −20 °C, protected from light and moisture; shelf life 24 months from the manufacture date.

This product is intended for laboratory research use only (RUO). It is not a drug, food, cosmetic, or dietary supplement, and is not for human or veterinary use, ingestion, or diagnostic application. Handling is restricted to qualified research professionals operating in an appropriately equipped laboratory.

When the BPC-157 + TB-500 lyophilised vial is the right format

  • Two peptides, one reconstitution. A single cake carries 10 mg of each peptide, so one reconstitution gives a stock containing both at a fixed 1:1 mass ratio; changing the ratio means working from separate vials.
  • Equal mass is not equal moles. At 1419.5 and 889.0 g/mol, 10 mg + 10 mg is about 7.0 µmol of BPC-157 and 11.2 µmol of TB-500, a molar ratio of roughly 1 to 1.6; analysis that works in molar terms should use these figures.
  • Storage before and after preparation. Keep the sealed vial at −20 °C, protected from light and moisture; in solution, stability depends on the diluent and the temperature, for both components.

Studying one peptide alone, or need identical pre-weighed units of the pair? BPC-157 and TB-500 (Frag) are sold separately as vials, and BPC-157 Arginate + TB-500 Capsules carry the pair as solid units, with BPC-157 as the arginate salt. For laboratory research use only. Not for human or veterinary use.

Supplied for in-vitro laboratory research use only (RUO). Not a drug, food or supplement; not for human or veterinary use.

[04]

Quality & COA

Certificate of Analysis
Lot-specific COA with every order

Certificate of Analysis — lot-specific COA ships with every order and is available on request.

Each lot is tested by an independent third-party laboratory for identity (mass spectrometry) and purity (HPLC). The Certificate of Analysis for your specific batch ships with the order and is available on request — no house data, no exceptions.

HPLC purity
≥99% (HPLC)
Method
HPLC + MS
Endotoxin
Reported
[02]

Data Sheet

CAS number137525-51-0 (BPC-157) · 885340-08-9 (TB-500)
Purity≥99% (HPLC)
Physical formWhite lyophilized powder
QuantityBPC-157 10mg + TB-500 10mg
SolubilitySoluble in water
StorageStore at -20°C, protect from light
ReconstitutionReconstitute with bacteriostatic water or sterile saline.
Shelf life24 months from manufacture date
OriginEU · Slovakia
ClassificationResearch use only
[03]

Scientific References

01 Mateescu DM, Gavrilescu DM, Constantinescu FE, Oancea C, Ilie AC, Folescu R, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5). PMID: 42198317. doi:10.3390/pharmaceutics18050625. PubMed 02 Yuan C, Demers A, Silva-Ortiz V, Hasoon JJ, Lee W, Dave K, et al. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. Int J Mol Sci. 2026;27(6). PMID: 41898733. doi:10.3390/ijms27062876. PubMed 03 McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID: 40789979. doi:10.1007/s12178-025-09990-7. PubMed 04 Sikiric P, Boban Blagaic A, Strbe S, Beketic Oreskovic L, Oreskovic I, Sikiric S, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024;17(4). PMID: 38675421. doi:10.3390/ph17040461. PubMed 05 Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-80. PMID: 21030672. doi:10.1152/japplphysiol.00945.2010. PubMed 06 Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-61. PMID: 20225319. doi:10.1002/jor.21107. PubMed 07 Sebecić B, Nikolić V, Sikirić P, Seiwerth S, Sosa T, Patrlj L, et al. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation. Bone. 1999;24(3):195-202. PMID: 10071911. doi:10.1016/s8756-3282(98)00180-x. PubMed 08 Petek M, Sikiric P, Anic T, Buljat G, Separovic J, Stancic-Rokotov D, et al. Pentadecapeptide BPC 157 attenuates gastric lesions induced by alloxan in rats and mice. J Physiol Paris. 1999;93(6):501-4. PMID: 10672996. doi:10.1016/s0928-4257(99)00120-5. PubMed 09 Di H, Huang J, Zhang D, Ni F, Zheng R, Geng H. Thymosin beta 4: An emerging therapeutic candidate for kidney diseases. Peptides. 2026;195:171467. PMID: 41570941. doi:10.1016/j.peptides.2026.171467. PubMed 10 Faa G, Messana I, Coni P, Piras M, Pichiri G, Piludu M, et al. Thymosin β(4) and β(10) Expression in Human Organs during Development: A Review. Cells. 2024;13(13). PMID: 38994967. doi:10.3390/cells13131115. PubMed 11 Mason WJ, Vasilopoulou E. The Pathophysiological Role of Thymosin β4 in the Kidney Glomerulus. Int J Mol Sci. 2023;24(9). PMID: 37175390. doi:10.3390/ijms24097684. PubMed 12 Xing Y, Ye Y, Zuo H, Li Y. Progress on the Function and Application of Thymosin β4. Front Endocrinol (Lausanne). 2021;12:767785. PMID: 34992578. doi:10.3389/fendo.2021.767785. PubMed 13 He S, Yuan M, Feng C, Zhang Y, Che J. Low-Temperature Fabrication of Thymosin β4-Loaded Soluble Microneedles to Promote Wound Healing by Specific Binding to Downregulated Immune Regulators Vsig4 and IL22rɑ2. Adv Healthc Mater. 2026;15(12):e04878. PMID: 41467542. doi:10.1002/adhm.202504878. PubMed 14 Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(14):2103-5. PMID: 14500546. doi:10.1096/fj.03-0121fje. PubMed 15 Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. PMID: 22962027. doi:10.1002/dta.1402. PubMed

References are illustrative of the research literature surrounding this compound. All claims relate to in-vitro and animal models only.

[05]

FAQ

No. This listing is a lyophilised vial with 10 mg of BPC-157 and 10 mg of TB-500 (Ac-LKKTETQ, thymosin β4 residues 17–23) that the laboratory reconstitutes; its BPC-157 is not the arginate salt. BPC-157 Arginate + TB-500 Capsules are a separate product: 60 pre-weighed capsules of 250 + 250 mcg in which BPC-157 is the arginate salt (same sequence, different salt form). The TB-500 component is the same fragment in both. For laboratory research use only. Not for human or veterinary use.

It is a single co-formulated, lyophilized vial pairing two extensively studied regenerative-research peptides: BPC-157 (10 mg), a gastric-derived 15-mer, and TB-500 (10 mg), the acetylated thymosin beta-4 fragment Ac-LKKTETQ (residues 17–23). It is supplied strictly as a Research Use Only reference material for in vitro and animal tissue-repair and cytoprotection studies.

The blend pairs them because BPC-157 and TB-500 act through different molecular pathways in tissue-repair models, so they are studied as complementary rather than overlapping reagents. Co-formulating both in one vial lets researchers investigate them together under identical conditions. For research use only, in vitro and animal models.

The blend co-formulates 10 mg BPC-157 and 10 mg TB-500 in one vial, reconstituted together, so the two are always studied at a fixed combined ratio. Buying them separately lets you vary each peptide independently. The BPC-157 amount matches the standalone 10 mg BPC-157 vial; the TB-500 in the blend is the Ac-LKKTETQ fragment, whose standalone equivalent is TB-500 (Frag) (2 mg vial), not the 10 mg full-length TB-500 vial. Both formats are research use only.

The BPC-157 + TB-500 blend contains two repair peptides (10 mg each). GLOW adds GHK-Cu (50 mg), a copper-binding tripeptide studied in skin-regeneration and tissue-repair research, making it a three-peptide formulation. Choose the two-peptide blend for a simpler system, or GLOW to include the copper peptide. Research use only.

Not exactly. The blend contains 10 mg BPC-157, matching the standalone BPC-157 vial, and 10 mg of TB-500 as the Ac-LKKTETQ fragment (thymosin beta-4 residues 17–23). Condor's standalone 10 mg TB-500 vial is full-length thymosin beta-4, a different molecule; the fragment's standalone equivalent is TB-500 (Frag), currently a 2 mg vial. In the blend both peptides are co-formulated and reconstituted together at a fixed ratio. Research use only, in vitro and animal models.

Purity is verified per component. For blends, the >=99% HPLC specification applies to each peptide individually, confirmed by independent third-party testing before co-formulation, with a batch Certificate of Analysis. To request the COA covering both components for a specific lot, contact info@condorresearch.com.

Both peptides are water-soluble, so one diluent reconstitutes the blend in the lab. For example, adding 2 mL of bacteriostatic water to the 20 mg vial (10 mg + 10 mg) gives 5 mg/mL BPC-157 and 5 mg/mL TB-500; adjust volume for other target concentrations. For research preparation only, not human use.

Yes. Condor supplies the BPC-157 + TB-500 blend strictly as a Research Use Only (in vitro) reference material to professionals and institutions, not as a medicine or product for human or veterinary use. Buyers are responsible for confirming import legality in their country. Questions: info@condorresearch.com.

Store the sealed blend vial at -20C, protected from light; shelf life is 24 months from manufacture. Lyophilized peptide is stable for short room-temperature transit, so cold-pack shipping is generally not required. All preparation and handling is for in vitro and animal research only, never human or veterinary use.

Condor Research supplies BPC-157 + TB-500 directly, dispatched from our EU facility in Slovakia to the EU, EEA, UK and Switzerland. Deliveries to EU destinations clear no third-country customs, and shipping is calculated at checkout. Supplied strictly as a research-use-only reference material — not for human or veterinary use.

[06]

Reviews

Leave a review
Earn 250 points for a verified review (account required).

No verified reviews yet.

Leave a review

Related compounds

Tissue repair

BPC-157

5 mg, lyophilised≥99% HPLC
€39.99€35.99 each from 10
Tissue repair

TB-500

5 mg, lyophilised≥99% HPLC
€59.99€53.99 each from 10
Tissue repair

TB-500 Capsules

60 capsules × 500 mcg≥99% HPLC
€164.90€148.41 each from 10
Blends

GLOW (GHK-Cu + BPC-157 + TB-500)

70 mg, 3-peptide blend≥99% HPLC
€159.99€143.99 each from 10